Abstracts tagged "comparative effectiveness and harms and rheumatoid arthritis (RA)"

Abstract Number: 473 • 2017 ACR/ARHP Annual Meeting
Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?
Sergio Schwartzman¹, Lorie A. Ellis², Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Shelly Kafka³, ¹Weill Cornell Medical College, New York, NY, ²Janssen HECOR Immunology, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 2529 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Marina Machado¹, Cristiano S. Moura², Hassan Behlouli¹, Jeffrey R. Curtis³ and Sasha Bernatsky⁴, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor approved in the USA in November 2012 for the treatment of rheumatoid arthritis (RA). As the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].